CN108467873A - 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 - Google Patents
一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 Download PDFInfo
- Publication number
- CN108467873A CN108467873A CN201810215804.1A CN201810215804A CN108467873A CN 108467873 A CN108467873 A CN 108467873A CN 201810215804 A CN201810215804 A CN 201810215804A CN 108467873 A CN108467873 A CN 108467873A
- Authority
- CN
- China
- Prior art keywords
- sgrna
- seq
- model
- animal
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 181
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 74
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 69
- 108091033409 CRISPR Proteins 0.000 claims abstract description 27
- 239000013612 plasmid Substances 0.000 claims abstract description 22
- 230000008685 targeting Effects 0.000 claims abstract description 17
- 238000011160 research Methods 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 12
- 238000002054 transplantation Methods 0.000 claims abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 174
- 108090000623 proteins and genes Proteins 0.000 claims description 93
- 210000004027 cell Anatomy 0.000 claims description 82
- 108091034117 Oligonucleotide Proteins 0.000 claims description 66
- 108020004414 DNA Proteins 0.000 claims description 63
- 241000699670 Mus sp. Species 0.000 claims description 54
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- 239000000969 carrier Substances 0.000 claims description 47
- 206010061598 Immunodeficiency Diseases 0.000 claims description 42
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 42
- 230000007813 immunodeficiency Effects 0.000 claims description 42
- 238000010171 animal model Methods 0.000 claims description 36
- 210000001519 tissue Anatomy 0.000 claims description 30
- 230000002441 reversible effect Effects 0.000 claims description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 27
- 240000002853 Nelumbo nucifera Species 0.000 claims description 26
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 26
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 26
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 23
- 230000007812 deficiency Effects 0.000 claims description 23
- 239000003550 marker Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 210000000822 natural killer cell Anatomy 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 18
- 238000002347 injection Methods 0.000 claims description 18
- 238000010276 construction Methods 0.000 claims description 17
- 238000012216 screening Methods 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 16
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 15
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 15
- 238000010362 genome editing Methods 0.000 claims description 15
- 230000036039 immunity Effects 0.000 claims description 15
- 210000000987 immune system Anatomy 0.000 claims description 14
- 241000283984 Rodentia Species 0.000 claims description 13
- 238000012795 verification Methods 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 230000002950 deficient Effects 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 12
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 11
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 11
- 238000000137 annealing Methods 0.000 claims description 11
- 238000011144 upstream manufacturing Methods 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 10
- 238000013518 transcription Methods 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 230000029087 digestion Effects 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 8
- 238000004925 denaturation Methods 0.000 claims description 8
- 230000036425 denaturation Effects 0.000 claims description 8
- 235000013601 eggs Nutrition 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 108700024394 Exon Proteins 0.000 claims description 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 7
- 238000011580 nude mouse model Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000003044 adaptive effect Effects 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000012239 gene modification Methods 0.000 claims description 5
- 230000005017 genetic modification Effects 0.000 claims description 5
- 235000013617 genetically modified food Nutrition 0.000 claims description 5
- 230000013011 mating Effects 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 108700022368 Whn Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000005755 formation reaction Methods 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 230000000857 drug effect Effects 0.000 claims description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 208000031873 Animal Disease Models Diseases 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 238000012356 Product development Methods 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 238000011558 animal model by disease Methods 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims description 2
- 238000007877 drug screening Methods 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000037189 immune system physiology Effects 0.000 claims description 2
- 230000006651 lactation Effects 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 17
- 238000005516 engineering process Methods 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 3
- 108020005004 Guide RNA Proteins 0.000 description 66
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 25
- 238000011282 treatment Methods 0.000 description 19
- 229940090044 injection Drugs 0.000 description 16
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 16
- 239000000575 pesticide Substances 0.000 description 16
- 229960004316 cisplatin Drugs 0.000 description 14
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 14
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 229930012538 Paclitaxel Natural products 0.000 description 11
- 229960001592 paclitaxel Drugs 0.000 description 11
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 10
- 229960001756 oxaliplatin Drugs 0.000 description 10
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 9
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 229960005277 gemcitabine Drugs 0.000 description 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 7
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 7
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 7
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 6
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 238000011579 SCID mouse model Methods 0.000 description 6
- 229960004117 capecitabine Drugs 0.000 description 6
- 229960004562 carboplatin Drugs 0.000 description 6
- 229940044683 chemotherapy drug Drugs 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000004976 peripheral blood cell Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000000973 chemotherapeutic effect Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 208000003950 B-cell lymphoma Diseases 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 241000699729 Muridae Species 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 229940125644 antibody drug Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 230000005740 tumor formation Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 238000011789 NOD SCID mouse Methods 0.000 description 3
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 3
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 3
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 3
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229960005079 pemetrexed Drugs 0.000 description 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001501969 Neacomys Species 0.000 description 2
- 241000904014 Pappus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101150036449 SIRPA gene Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 101150034785 gamma gene Proteins 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000398985 Cricetidae Species 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 241001416488 Dipodidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100027280 Fanconi anemia group A protein Human genes 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- 241001416537 Gliridae Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101000914673 Homo sapiens Fanconi anemia group A protein Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- -1 IL-7-IL-9 Proteins 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102100030704 Interleukin-21 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102220470475 L-seryl-tRNA(Sec) kinase_C57L_mutation Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 244000134336 Malus baccata Species 0.000 description 1
- 235000005079 Malus baccata Nutrition 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000393460 Peromyscus nasutus Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229940081995 fluorouracil injection Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 230000014725 late viral mRNA transcription Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 229940108949 paclitaxel injection Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 201000002341 thymus lymphoma Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
10×KOD缓冲液 | 2μL |
dNTP(2mM) | 2μL |
MgSO4(25mM) | 0.8μL |
上游引物(10μM) | 0.6μL |
下游引物(10μM) | 0.6μL |
鼠尾gDNA | 200ng |
KOD(200U) | 0.6μL |
H2O | 补至20μL |
表面标记分子 | B-NDG#1 | B-NDG#2 | B-NDG#3 | 平均值 | SD | |
T细胞 | CD3+ | 1.20% | 0.35% | 0.14% | 0.56% | 0.56% |
CD4+T细胞 | CD3+CD4+ | 0.21% | 0.00% | 0.00% | 0.07% | 0.12% |
CD8+T细胞 | CD3+CD8+ | 0.00% | 0.14% | 0.00% | 0.05% | 0.08% |
B细胞 | CD3-CD19+ | 0.09% | 0.00% | 0.00% | 0.03% | 0.05% |
NK细胞 | CD3-CD49b+ | 1.34% | 1.24% | 1.54% | 1.37% | 0.15% |
B-NDG | NSG | NOG | |
hCD45+(%) | 85.2% | 68.9% | 58% |
hCD3+T(%) | 49% | 42.8% | 39% |
hCD19+B(%) | 25.2% | 7.8% | 16% |
Claims (50)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/079365 WO2018166534A1 (en) | 2017-03-17 | 2018-03-16 | Immunodeficient non-human animal |
US16/435,080 US10820580B2 (en) | 2017-03-17 | 2019-06-07 | Immunodeficient non-human animal |
US17/030,995 US20210105982A1 (en) | 2017-03-17 | 2020-09-24 | Immunodeficient non-human animal |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710160547 | 2017-03-17 | ||
CN2017101605471 | 2017-03-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108467873A true CN108467873A (zh) | 2018-08-31 |
CN108467873B CN108467873B (zh) | 2020-03-13 |
Family
ID=63264501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810215804.1A Active CN108467873B (zh) | 2017-03-17 | 2018-03-15 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
Country Status (3)
Country | Link |
---|---|
US (2) | US10820580B2 (zh) |
CN (1) | CN108467873B (zh) |
WO (1) | WO2018166534A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109486860A (zh) * | 2018-12-04 | 2019-03-19 | 江苏集萃药康生物科技有限公司 | 一种tigit人源化小鼠模型的构建方法及其应用 |
CN110100788A (zh) * | 2019-05-14 | 2019-08-09 | 四川省人民医院 | 基于基因操作策略构建疾病模型的方法和应用 |
CN111154809A (zh) * | 2020-01-09 | 2020-05-15 | 电子科技大学附属医院·四川省人民医院 | 利用基因操作技术构建肾小球疾病模型的方法和应用 |
WO2021136537A1 (en) * | 2019-12-31 | 2021-07-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα/CD47 |
US11723348B2 (en) | 2017-03-31 | 2023-08-15 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified mice expressing humanized CD47 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017053729A1 (en) | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
WO2020135518A1 (en) | 2018-12-25 | 2020-07-02 | Biocytogen Jiangsu Co., Ltd. | Genetically modified non-human animal with human or chimeric il15 |
US20220408704A1 (en) * | 2019-11-01 | 2022-12-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with human or chimeric thpo |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104561095A (zh) * | 2015-01-27 | 2015-04-29 | 长春力太生物技术有限公司 | 一种能够生产人神经生长因子的转基因小鼠的制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JP3753321B2 (ja) | 2000-12-01 | 2006-03-08 | 財団法人実験動物中央研究所 | 異種細胞の生着、分化および増殖に適したマウスの作出方法、該方法により作出されたマウスならびにそのマウスの用途 |
US8569573B2 (en) * | 2007-06-05 | 2013-10-29 | Oregon Health & Science University | Method of expanding human hepatocytes in vivo |
CN103409468B (zh) * | 2013-03-20 | 2015-08-12 | 中国科学院广州生物医药与健康研究院 | 一种免疫缺陷小鼠模型的建立方法 |
CA2908697C (en) * | 2013-04-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
DK2908626T3 (en) | 2013-10-15 | 2017-03-20 | Regeneron Pharma | Humanized IL-15 animals |
WO2015155904A1 (ja) * | 2014-04-07 | 2015-10-15 | 学校法人自治医科大学 | 遺伝子ノックアウトブタ |
KR102658190B1 (ko) * | 2015-04-13 | 2024-04-17 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법 |
CN106119284A (zh) * | 2016-06-27 | 2016-11-16 | 北京维通达生物技术有限公司 | 一种用于构建免疫缺陷动物模型的产品及其应用 |
US10912287B2 (en) | 2016-06-28 | 2021-02-09 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd | Genetically modified mice expressing humanized PD-1 |
WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
WO2018041121A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ctla-4 |
US11279948B2 (en) | 2016-08-31 | 2022-03-22 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric OX40 |
WO2018041118A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric pd-l1 |
WO2018068756A1 (en) | 2016-10-14 | 2018-04-19 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric btla |
CN106755115A (zh) * | 2017-02-06 | 2017-05-31 | 南方医科大学 | 一种免疫缺陷大鼠模型的构建方法 |
-
2018
- 2018-03-15 CN CN201810215804.1A patent/CN108467873B/zh active Active
- 2018-03-16 WO PCT/CN2018/079365 patent/WO2018166534A1/en active Application Filing
-
2019
- 2019-06-07 US US16/435,080 patent/US10820580B2/en active Active
-
2020
- 2020-09-24 US US17/030,995 patent/US20210105982A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104561095A (zh) * | 2015-01-27 | 2015-04-29 | 长春力太生物技术有限公司 | 一种能够生产人神经生长因子的转基因小鼠的制备方法 |
Non-Patent Citations (2)
Title |
---|
CHIA-WEICHANG等: "Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting", 《CELL REPORTS》 * |
信吉阁; 曾养志;: "基于CRISPR/Cas9技术构建严重联合免疫缺陷小鼠", 《中国实验动物学报 》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11723348B2 (en) | 2017-03-31 | 2023-08-15 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified mice expressing humanized CD47 |
CN109486860A (zh) * | 2018-12-04 | 2019-03-19 | 江苏集萃药康生物科技有限公司 | 一种tigit人源化小鼠模型的构建方法及其应用 |
CN109486860B (zh) * | 2018-12-04 | 2022-04-08 | 江苏集萃药康生物科技股份有限公司 | 一种tigit人源化小鼠模型的构建方法及其应用 |
CN110100788A (zh) * | 2019-05-14 | 2019-08-09 | 四川省人民医院 | 基于基因操作策略构建疾病模型的方法和应用 |
WO2021136537A1 (en) * | 2019-12-31 | 2021-07-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα/CD47 |
CN113122574A (zh) * | 2019-12-31 | 2021-07-16 | 百奥赛图(北京)医药科技股份有限公司 | 一种免疫缺陷型人源化非人动物的构建方法 |
CN111154809A (zh) * | 2020-01-09 | 2020-05-15 | 电子科技大学附属医院·四川省人民医院 | 利用基因操作技术构建肾小球疾病模型的方法和应用 |
CN111154809B (zh) * | 2020-01-09 | 2020-11-27 | 电子科技大学附属医院·四川省人民医院 | 利用基因操作技术构建肾小球疾病模型的方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
US10820580B2 (en) | 2020-11-03 |
US20190320631A1 (en) | 2019-10-24 |
US20210105982A1 (en) | 2021-04-15 |
CN108467873B (zh) | 2020-03-13 |
WO2018166534A1 (en) | 2018-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108467873A (zh) | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 | |
US11234420B2 (en) | Method for constructing PD-1 gene modified humanized animal model and use thereof | |
Kim et al. | Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia | |
Viatour et al. | Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family | |
CN110055223A (zh) | 一种B2m基因改造的免疫缺陷动物的制备方法及其应用 | |
CN107815465A (zh) | 人源化基因改造动物模型的制备方法及应用 | |
CN108401987A (zh) | 经遗传修饰的非人动物及其使用方法 | |
CN106536546A (zh) | 表达人epo的经遗传修饰的非人动物 | |
SA516380143B1 (ar) | تركيبات وطرق لعلاج أمراض الهيموجلوبين | |
CN107815466A (zh) | 人源化基因改造动物模型的制备方法及应用 | |
CN107815467A (zh) | 人源化基因改造动物模型的制备方法及应用 | |
CN104955326A (zh) | 经遗传修饰的非人动物及其使用方法 | |
CN109136261A (zh) | 人源化cd28基因改造动物模型的制备方法及应用 | |
CN110139675A (zh) | 用具有工程化稳定的内源性foxp3基因表达的cd4 t细胞治疗自身免疫疾病的方法 | |
Briukhovetska et al. | T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis | |
CN109415698A (zh) | 工程化Treg细胞 | |
CN109136275A (zh) | 人源化gitr基因改造动物模型的制备方法及应用 | |
CN108300738B (zh) | 一种nod遗传背景的中性粒细胞缺失的人源化小鼠模型的制备方法 | |
US20220017715A1 (en) | Compositions and Methods for Efficacy Enhancement of T-Cell Based Immunotherapy | |
CN111647623B (zh) | 一种sirpa人源化动物模型的构建方法及其应用 | |
CN110195057A (zh) | Hr基因经遗传修饰的非人动物或其子代的制备方法及应用 | |
CN107955817A (zh) | 人源化基因改造动物模型的制备方法及应用 | |
CN111372449A (zh) | 免疫缺陷小鼠 | |
WO2017049002A1 (en) | A humanized mouse model of de novo human acute myeloid leukemia with a matching human immune system | |
CN108300737A (zh) | 一种表型高度一致的恶性淋巴瘤模型的建立方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20191220 Address after: 226133 Building B10 of Biomedical Park, Linjiang New District, Haimen City, Nantong City, Jiangsu Province Applicant after: Jiangsu gene Biotechnology Co., Ltd. Applicant after: Beijing Biocytogen Co., Ltd. Address before: 101111 room 1201-1210, incubator center, 88 Chuang six street, Daxing District East Economic and Technological Development Zone, Beijing Applicant before: Beijing Biocytogen Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Building B10, biomedical science and Technology Innovation Park, Linjiang New District, Haimen City, Nantong City, Jiangsu Province Patentee after: BIOCYTOGEN JIANGSU GENE BIOTECHNOLOGY Co.,Ltd. Patentee after: Baccetus (Beijing) Pharmaceutical Technology Co.,Ltd. Address before: Building B10, biomedical science and Technology Innovation Park, Linjiang New District, Haimen City, Nantong City, Jiangsu Province Patentee before: BIOCYTOGEN JIANGSU GENE BIOTECHNOLOGY Co.,Ltd. Patentee before: BEIJING BIOCYTOGEN Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |